Ibandronic Acid Generics - Manufacturers & Suppliers
Boniva® (US & EU); Bondronat®(EU)
| Product/Composition:- | Ibandronic Acid |
|---|---|
| Strength:- | Tablet: 150 mg; Injection: 3mg/3ml |
| Form:- | Oral tablet and Intravenous injection |
| Reference Brands:- | Boniva® (US & EU); Bondronat®(EU) |
| MOQ | As per the manufacturer batch size |
| Get Quote Send Enquiry on WhatsApp | |
Ibandronic Acid (Bonviva® in the EU, Boniva® in the US) is a bisphosphonate used to treat and prevent postmenopausal osteoporosis. It reduces bone loss and fracture risk by inhibiting osteoclast activity. Available as a 150 mg oral tablet (monthly) or 3 mg IV injection (quarterly), it offers flexible dosing and high patient adherence. Widely marketed by Roche, it is a trusted option in B2B women’s health distribution across Europe and the United States.
Ibandronic Acid (marketed as Bonviva® in the EU and Boniva® in the US) is a bisphosphonate used for the treatment and prevention of postmenopausal osteoporosis. It works by inhibiting osteoclast-mediated bone resorption, increasing bone mineral density and reducing the risk of vertebral fractures. Available in oral 150 mg monthly tablets and 3 mg quarterly IV injections, Ibandronic Acid offers flexible dosing options to improve patient compliance. It is marketed in both regions by Roche and its affiliates, ensuring consistent quality and regulatory compliance. Ibandronic Acid is widely adopted in B2B pharmaceutical distribution for women’s health across Europe and North America.